Viewing Study NCT03876067



Ignite Creation Date: 2024-05-06 @ 12:53 PM
Last Modification Date: 2024-10-26 @ 1:05 PM
Study NCT ID: NCT03876067
Status: UNKNOWN
Last Update Posted: 2019-03-19
First Post: 2019-03-10

Brief Title: The Cardioprotective Effects of Adding Ozone To Cardioplegic Solution in Adult Cardiac Surgery
Sponsor: Assiut University
Organization: Assiut University

Study Overview

Official Title: The Cardioprotective Effects of Adding Ozone To Cardioplegic Solution in Adult Cardiac Surgery
Status: UNKNOWN
Status Verified Date: 2019-03
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: forty patients with age ranged between 40-70 years undergoing elective coronary artery bypass graft surgery with cardiopulmonary bypass will be included they will divided into two groups

Ozone Group in which Ozone will be added to cold blood cardioplegia Control Group in which in which only cold blood cardioplegia

Primary outcome

Pattern of recovery of myocardium after declamping of Aorta

1 Time of cardiac rhythm return after declamping
2 type of cardiac rhythm after declamping and rate of DC use

Secondary outcome

A-cardiac parameters

Post operative inotropic score
Incidence of post operative cardiac dysrhythmias
postoperative ejection fraction EF
Postoperative parameters of myocardial ischaemia
a- Troponin levels
b-Pro BNP
Histopathology of myocardial sample for detection of myocyte cellular edema as a marker of ischemic changes

B-non cardiac parameters

1 inflammatory markers 1 CRP 2 LN 3 PN
2 ICU stay
3 hospital stay
4 morbidity and mortality
Detailed Description: Ozone Administration Protocol

Our procedures for O3T application in CBP surgery conform to international guidelines of the Madrid Declaration on Ozone Therapy 32 M-O3T will be carried out as follows

50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 38 Na citrate solution Galenica Senese Industries Siena Italy as an anticoagulant will be previously added so that the bloodcitrate volume ratio was 91 After blood withdrawal the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 A corresponding volume 50 mL of gas was immediately added with an O3 concentration of 20-50 microgramsmL gas Ozone was produced by Medozon compact generator Herrmann Apparatebau GmbH Germany

The gas is immediately and continuously mixed with the blood in the bag for at least 5 min and with gentle rotating movement to avoid foaming Due to the blood viscosity the gas mixture does not instantaneously come into contact with the whole blood mass thus this mixing time is necessary During these 5 min of mixing the ozone totally reacted with both the potent antioxidants of plasma and the unsaturated lipids bound to albumin generating asmall amount of hydrogen peroxide and alkenals These two messengers were responsible for eliciting crucial biochemical reactions on both erythrocytes and within cells At this point the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia Thomsons cardioplegia this amount of ozonated blood will be added to each 500 ml of cardioplegic solution

Exclusion Criteria

The patient will be excluded from the study if he has any of the following

left ventricular ejection fraction 40
diabetic or other metabolic disorders
use of left ventricular assist devices
Renal failure or on hemodialysis
Hepatic dysfunction
Hypothyroidism
implanted pacemaker

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None